Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1516)	3/14/1998 5:31:00 AM
From: Maurice Winn	Read Replies (1) \| Respond to of 1762

Thanks for the comments Rick. While the tumor might recur wearing different clothing, it presumably take a bit of time to go through the necessary cell divisions and mutations. Just how long does it take a malignant B-cell to go through its reproductive cycle? I guess a few days judging from how fast a tumor can grow. In fact it must depend on the individual cell type somehow since the low grade ones seem to take ages - with patients lasting a decade. When they take blood to prepare the vaccine for the individual patient, they must be able to target the clothing which is present at that time. I thought that vaccine would act in a few days before the B-cells would have much chance to do much in the way of mutations into wolf2 clothing. But I guess there are a lot of them and one escapee malignant cell is all it takes. While the Russian 5 year plan "Everyone Shall Wear Size 8 Shoes" is efficient for production, individually tailored treatment seems obvious when DNA and those little bits of protein and individual mutation seem so personal. The argument against it has been cost. So give everyone cyclophosphamide. But with gene chip arrays and all that jazz, individual treatment is looking sensible. I don't know quite what "...antigen-pulsed dendritic cells..." means. In fact I have little idea at all. But it sounded good to me too. What does antigen-pulsed mean? I guess dentritic cells have dendrites. Some sort of morphology. Part of the "look through the microscope" definition of cells according to their shape I guess. I guess a naked vaccine is one without radioactive isotopes stuck on? Yes? That's what they mean by naked monoclonal antibodies. Then you mentioned "...an adjuvant within the same gene construct as the idiotype antigen". It is isn't that I don't know what you aren't talking about. I'm just not sure what you are. I guess it means that you find out what is the typical antigen sticking out in public, ready to get belted, then plonk something extra on the gene which is typical for the lymphoma. Which makes it easier to target the lymphoma cells. Thanks for the comments, Maurice

To: scaram(o)uche who wrote (1516)	4/10/1998 6:13:00 PM
From: Maurice Winn	Read Replies (2) \| Respond to of 1762

cancernet.nci.nih.gov Thanks BobLLL from Yahoo for the reference and comments: "There are two large studies going on now on to gather more data on Rituxan. Over a thousand patients in the two. A huge list of major cancer centers participating. Unlike the Oncolym study, these studies can be confirmed on the NCI site. Look for yourself, search for Lymphoma, Adult, NonHodgins/ Phase III/ Modality: monoclonal antibody Oh, yeah, you'll also see another study of Bexxar by another group of scientists too dumb to read this thread Nothing about Oncolym. I'll leave it to the bulls to explain why this also is irrelevant. After all, what does NCI know about this stuff?" Richard, just trying to tempt you to take an interest in IDPH, TCLN and CLTR. It isn't that I don't think CD20 MAbs won't be ineffective, its just that I'm unsure that they will. Meanwhile, [to those interested], Tarken's lymphoma was strongly CD20 positive, but no Rituxan treatment anyway! Does Rituxan have such cunning that it can discriminate between CD20 on intermediate grade which has changed from low grade and is ineffective on CD20 cells which are given the somewhat arbitrary designation intermediate grade instead of low grade or indolent. Since indolent can metamorphose into intermediate, the distinction seems capricious. Surely the only thing that matters in regard to Rituxan is strongly expressed CD20. Any ideas anyone? Why is Rituxan only effective on low grade CD20? Maurice